Major Shareholding Notification • Mar 6, 2024
Major Shareholding Notification
Open in ViewerOpens in native device viewer
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(th) of the Investment Company Act of 1940
| (Print or Type Responses) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Name and Address of Reporting Person Sabag Mark |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner |
|||||||||
| (Last) 124 Dvora HaNevi'a St., |
(First) C/O Teva Pharmaceutical Industries Ltd. |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024 |
X __ Officer (give title below) Other (specify below) EVP, International Markets |
|||||||
| (Street) Tel Aviv, L3 6944020 |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |
|||||||||
| (City) | (State) | (Zip) |
| 1.Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired | 5. Amount of Securities Beneficially | 7. Nature | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Instr. 3) | Date | l Execution Date, if Code | (A) or Disposed of (D) | Owned Following Reported | Ownership of Indirect | |||||
| (Month/Day/Year) any | (Instr. 8) | (Instr. 3, 4 and 5) | Transaction(s) | Form: | Beneficial | |||||
| ا (Month/Day/Year) | (Instr. 3 and 4) | Direct (D) Ownership | ||||||||
| or Indirect | (Instr. 4) | |||||||||
| (A) or | (1) | |||||||||
| Code | Amount | D) | Price | (Instr. 4) | ||||||
| 'Ordinary Shares (1) | 03/03/2024 | M | 24,900 | A | (2) | 367,181 | D | |||
| 'Ordinary Shares (1) | 03/04/2024 | M | 33,512 | A | (2) | 400.693 | D |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | |
|---|---|
| e.g. , puts, calls, warrants, options, convertible securities) |
| 1. Title of Derivative Security (Instr. 3) |
2 Conversion Date Price of Derivative Security |
3. Transaction or Exercise (Month/Day/Year) any |
3A. Deemed Execution Date, if Transaction Derivative (Month/Day/Year) (Instr. 8) |
4. Code |
1 - 0 - 7 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
Derivative Derivative Security (Instr. 5) |
8. Price of 9. Number of Securities Beneficially Owned Following |
10 Ownership of Indirect Form of Derivative Security: Direct (D) |
11. Nature Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | (A) | (D) | Date Exercisable Date |
Expiration | Reported Amount or Title Number of Shares |
Transaction(s) (Instr. 4) |
or Indirect (1) (Instr. 4) |
||||||||
| Restricted Share Units |
(2) | 03/03/2024 | M | 24,900 | (3) | (3) | Ordinary Shares (1) |
24,900 | \$ 0 | 74,701 | D | ||||
| Restricted Share Units |
(2) | 03/04/2024 | M | 33,512 | (4) | (4) | Ordinary Shares (1) |
33,512 | \$ 0 | 67,024 | D | ||||
| Restricted Share Units |
(2) | 03/04/2024 | A | 74,404 | (5) | (5) | Ordinary Shares (1) |
74,404 | \$ 0 | 74,404 | D |
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 03/05/2024
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.